Prior clinical studies have investigated the impact of several donor-graft characteristics on the outcome of patients after hematopoietic cell transplantation. [1] [2] [3] [4] [5] Recently, Yakoub-Agha et al. 6 presented a study in Leukemia, demonstrating that a high percentage of CD4 þ CCR7 þ T cells in marrow or peripheral blood stem cell (PBSC) grafts significantly correlated with the incidence of acute graft-versus-host disease (GVHD). A current hypothesis concerning its pathogenesis is that epithelial damage in the gut due to components of conditioning facilitates the translocation of lipopolysaccharide, a cell wall component of Gram-negative bacteria into the blood. There, it can initiate proinflammatory cytokine production and activation of different immune cascades, finally leading to a clinical manifestation of GVHD. 7 In fact, Toll-like receptors (TLRs) 2 and 4 have been identified as the most important receptors for lipopolysaccharide. 8 While the expression and function of TLRs on monocytes have already been widely studied, their role on T cells is not well understood. 9 Recent data showed that TLR4 mutation could protect from GVHD 10 and that TLR expression on regulatory T cells abrogates their suppressive properties. 11 As donor T cells are supposed to be the major effector cells in GVHD, we sought to explore if there is a relevant expression of TLRs on CD4 þ and CD8 þ T cells in PBSC grafts and study its impact on the development of GVHD, treatment-related mortality, relapse and overall survival of 63 patients receiving unrelated peripheral blood stem cell transplant (PBSCT).
All patients and their respective unrelated donors were treated within protocols at the University Hospital of Dresden. Patient and donor pairs were matched at least in 9 out of 10 alleles (n ¼ 17), whereas a complete match (10 out of 10) was observed in 46 patients. Written informed consent was obtained from each patient and donor and all protocols were approved by the institutional review board of the University Hospital Dresden. Patient and graft characteristics are given in Table 1 . All patients received a myeloablative conditioning regimen prior to PBSCT and cyclosporine/methotrexate as GVHD prophylaxis as described recently. 5 No anti-thymocyte globulin was used during conditioning. All patients received unmanipulated PBSCs on day 0. Cryopreserved aliquots of the donor grafts were thawed and cell-surface antigens were stained using the following series of monoclonal anti-human antibodies: anti-human CD4-PE, anti-human CD3-PECy5, anti-human CD8-FITC (Beckman Coulter, Paris, France), anti-human CD4-FITC (DakoCytomation, Glostrup, Denmark), antihuman TLR2-PE and antihuman TLR4-PE (eBioscience, San Diego, CA, USA). The following antibodies were used as isotype controls: IgG1-PECy5 (BD Pharmingen, Heidelberg, Germany), IgG1-FITC and IgG1-PE (Beckman Coulter, France).
Expectedly, TLRs were insignificantly expressed on T cells in peripheral blood of healthy donors (TLR2: o1.0%, TLR4 o0.5% of T cells, n ¼ 6, data not shown). In contrast, a distinct upregulation of these receptors was detected on T cells within the grafts. TLR2 and TLR4 expression on CD4 þ T cells ranged from 1.2 to 12.3% (median 3.1%) for TLR2, and from 1.2 to 12.0% (median 3.7) for TLR4. Among the CD8 þ T cells, 0.9-16.1% (median 3.3%) expressed TLR2 and 0.7-13.3% (median 3.5%) expressed TLR4. To determine whether this upregulation was due to granulocyte colony-stimulating factor, cryopreservation or mechanical forces during apheresis, we also analyzed fresh apheresis products and the peripheral blood of granulocyte colony-stimulating factor-mobilized donors prior to and after apheresis (n ¼ 7). In the latter case, no upregulation was seen (data not shown). In fresh apheresis products, however, we again observed an upregulation of TLR2 and TLR4 (Figure 1 ), but, as observed in the cryopreserved grafts, this upregulation was not specific for lymphocytes, as the intensity of TLR expression on cells other than T cells was increased as well ( Figure 1 ). These data are in accordance with the notion that the cell-processing procedure during a PBSC harvest rather than granulocyte-colony-stimulating factor alone is responsible for the upregulation of TLR2 and TLR4 on T-cell subsets in the graft.
Among 63 patients, 29 (46%) developed acute GVHD grade 0-I, and 34 (54%) patients developed grade II-IV, whereas extensive chronic GVHD was seen in 24 (46%) patients evaluated. Currently, 27 patients (42%) are still alive with a median follow-up of 30.1 months (range 0.6-62), with 17 (27%) having relapsed. Neither the overall CD3 þ , CD4 þ and CD8 þ cell dose nor the extent of expression of TLR2 and TLR4 on CD4 þ and CD8 þ T cells showed a significant association with the incidence of acute or chronic GVHD, relapse and overall survival (data not shown).
Treatment-related mortality from infectious complications was observed in 10 patients (16%). We could not see any significant correlation between TLR2-and TLR4-expressing CD8 þ T cells and death from fatal infections (data not shown). However, higher expression of TLR2 (P ¼ 0.03) and TLR4 (P ¼ 0.007; Figure 2 ) on CD4 þ T cells was significantly associated with an increased cumulative incidence of death Advanced disease: acute leukemias beyond first complete remission (CR), refractory anemia with excess of blasts, multiple myeloma, Hodgkin and non-Hodgkin lymphoma beyond second CR or refractory; Less advanced disease: non-Hodgkin lymphoma in first/ second CR and untreated first relapse, acute leukemias in first CR, refractory anemias.
Letters to the Editor from fatal infections. The results suggest a possible link to in-vitro results demonstrating that activated CD4 þ T cells expressing TLR2 or TLR4 excessively produce interferon-g and tumor necrosis factor-a upon ligation. 9, 12 Additionally, upregulation of TLR on Tregs has also been shown to inhibit their function, thus possibly influencing also patient outcome after allogeneic PBSCT. 11 Given the fact that donor-specific single nucleotide polymorphisms (SNPs) have been associated with expression levels of TLR and autoimmune disease, 13 SNPs for TLR2-R753Q, TLR4-D299G and TLR4-T399I were determined using a PCRbased restriction-fragment length polymorphism technique after extraction of donor DNA as described. [13] [14] [15] [16] As a result, the given SNPs were found in 8.6, 10.3 and 10.0% of the donors, respectively, but did not show any association either with the expression levels of TLR2/4 on T cells or with clinical end points (data not shown). We further extended the SNP analysis to a major adaptor protein for both TLR2 and TLR4 called TIRAP (TIRAP-S180L), which had been shown to protect from severe infections. 17 This SNP was found in 26% of donors, but again did not correlate with clinical end points (data not shown).
Figure 1
Phenotypic characterization of Toll-like receptor (TLR) 2 and TLR4-expressing T cells in the blood of a donor after 5 days of granulocyte colony-stimulating factor stimulation (a) and in the fresh peripheral blood stem cell graft (b). Phenotypic characterization was performed after gating first on the total lymphocyte population.
Figure 2
Cumulative incidence estimates of fatal infections according to donor TLR4 þ CD4 þ cell dose in the graft: patients receiving a TLR4 þ CD4 þ cell dose above the median (47.62 Â 10 6 kg -1 ) experienced significantly more fatal infections (P ¼ 0.007).
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Taken together, the data show a yet unknown upregulation of TLR2 and TLR4 on T cells in PBSC grafts and suggest a possible association between their infused amount and the outcome of patients receiving unrelated PBSCT. Therefore, further studies are warranted to determine the reasons for the varying degree of upregulation of TLRs during the apheresis procedure as well as the functional capacity of this T-cell subset in the setting of allogeneic PBSCT.
MicroRNA expression in lymphocyte development and malignancy MicroRNAs are a recently discovered class of naturally occurring short noncoding RNA molecules that negatively regulate eukaryotic gene expression through binding to complementary sequences in the 3 0 -UTR of target mRNA. There is rapidly accumulating evidence to suggest that dysfunctional expression of microRNAs is a common feature of hematological malignancy.
1 With the exception perhaps of chronic lymphocytic leukemia (CLL) however, the role of microRNAs in hematological malignancies is not well understood; in particular, to date there has been no systematic identification of aberrantly expressed microRNAs in lymphoma. To address this, we used microarray analysis to look at microRNA expression in a wide range of hematological cell lines (n ¼ 40) including all major types of B-and T-cell lymphoma (n ¼ 29), nonmalignant lymphoproliferative disorder, persistent polyclonal B-cell lymphocytosis (PPBL; n ¼ 3), T-cell acute lymphoblastic leukemia (T-ALL; n ¼ 6) and acute myeloid leukemia (AML; n ¼ 2; Table 1 ). To compare these samples with their normal counterpart cells of origin, as well as looking at the role of microRNAs in lymphocyte development, we also examined expression in the major B-lymphocyte developmental stages and mature T-cell subsets (n ¼ 12; Table 1 ).
Samples (approximately 10 7 cells) were first purified into microRNA-enriched fractions using miREasy columns from Qiagen (Crawley, UK) and 500 ng labeled with either Cy3 or Cy5 using the Array 900microRNA RT kit from Genisphere
